Evidence map›Paper›PMID 41256702›Full record

ArticlebioRxiv : the preprint server for biology2025

Random forest model improves annotation and discovery of variants of uncertain significance in Alzheimer's and other neurological disorders.

Caroline Jonson, Mary B Makarious, Mathew J Koretsky, Dan Vitale, Liya Rabkina, Argentina Lario Lago, Manizhe Eslami-Amirabadi, Eliana Marisa Ramos, Priyanka Narayan, Jennifer S Yokoyama and 5 more

Abstract readPreprint
In one paragraph

Article in bioRxiv : the preprint server for biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Caroline JonsonCenter for Alzheimer's and Related Dementias, Bethesda, MD, USA 20892.ORCID 0000-0001-7049-6281
Mary B MakariousCenter for Alzheimer's and Related Dementias, Bethesda, MD, USA 20892.
Mathew J KoretskyCenter for Alzheimer's and Related Dementias, Bethesda, MD, USA 20892.
Dan VitaleCenter for Alzheimer's and Related Dementias, Bethesda, MD, USA 20892.
Liya RabkinaMemory and Aging Center, Department of Neurology, Weill Institute for Neurosciences, University of California, San Francisco, CA, USA.
Argentina Lario LagoMemory and Aging Center, Department of Neurology, Weill Institute for Neurosciences, University of California, San Francisco, CA, USA.
Manizhe Eslami-AmirabadiMemory and Aging Center, Department of Neurology, Weill Institute for Neurosciences, University of California, San Francisco, CA, USA.
Eliana Marisa RamosDepartment of Neurology, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, USA.
Priyanka NarayanCenter for Alzheimer's and Related Dementias, Bethesda, MD, USA 20892.
Jennifer S YokoyamaMemory and Aging Center, Department of Neurology, Weill Institute for Neurosciences, University of California, San Francisco, CA, USA.
Andrew B SingletonCenter for Alzheimer's and Related Dementias, Bethesda, MD, USA 20892.
Cornelis BlauwendraatCoalition for Aligning Science, Chevy Chase, MD, USA; Global Parkinson's Genetics Program, Chevy Chase, MD, USA; Aligning Science Across Parkinson's (ASAP), Chevy Chase, MD, USA.
Mark R CooksonCenter for Alzheimer's and Related Dementias, Bethesda, MD, USA 20892.
Mike A NallsCenter for Alzheimer's and Related Dementias, Bethesda, MD, USA 20892.
Hampton L LeonardCenter for Alzheimer's and Related Dementias, Bethesda, MD, USA 20892.

Funding

STRIDESOT2OD027852 · OD · FOUR POINTS TECHNOLOGY, LLC · PI Joel A Lipkin · 2018 to 2026
$255.6M
STRIDES OT2OD027060 · OD · CARAHSOFT TECHNOLOGY CORPORATION · PI Terry Drinkwine · 2018 to 2026
$134.1M
Technology and Remote Assessment CoreU19AG063911 · NIA · MAYO CLINIC ROCHESTER · PI ADAM L. BOXER, Bradley F Boeve · 2019 to 2026
$120.9M
TDP-43 Loss-of-Function: Biology to BiomarkersP01AG019724 · NIA · UNIVERSITY OF PENNSYLVANIA · PI Jennifer Merrilees · 2002 to 2026
$67.2M
NIH STRIDES - Azure and Associated Services and Training.OT2OD032100 · OD · DELL FEDERAL SYSTEMS L.P. · PI Amy K HammondOdwyer, Erum Siddiqui · 2021 to 2026
$62.2M
Project 2: Biomarker Analysis, Non-Genetic Risk Factors, and Their Genetic InteractionsU19AG079774 · NIA · UNIVERSITY OF PENNSYLVANIA · PI HELENA Chang CHUI, Gyungah Jun · 2023 to 2026
$39.4M
Research Education ComponentP30AG062422 · NIA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Katherine P Rankin · 2019 to 2026
$36.9M
Tau Metabolism in FTD: From Gene Mutations to Molecular Chaperones and Lysosomal ProteasesU54NS123985 · NINDS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI AGARD, DAVID A., KAO, AIMEE · 2021 to 2025
$9.0M
US-South American Initiative for Genetic-Neural-Behavioral Interactions in Human Neurodegenerative ResearchR01AG057234 · NIA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Claudia Duran-Aniotz, Agustin M. Ibanez · 2019 to 2026
$6.1M
Elucidating clinical heterogeneity in early-onset AD via genomics, transcriptomics, and neuroimagingR01AG062588 · NIA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI YOKOYAMA, JENNIFER S · 2019 to 2023
$4.0M
Genome wide SNP analysis in Parkinson's diseaseZ01AG000949 · NIA · NATIONAL INSTITUTE ON AGING · PI SINGLETON, ANDREW B · 2006 to 2008
$2.6M
Intramural NIH HHS Z01 AG000949NIA NIH HHS P01 AG019724NIA NIH HHS P30 AG062422NIA NIH HHS R01 AG057234NIA NIH HHS R01 AG062588NIA NIH HHS U19 AG063911NIA NIH HHS U19 AG079774NIH HHS OT2 OD027060NIH HHS OT2 OD027852NIH HHS OT2 OD032100NINDS NIH HHS U54 NS123985
6 · The paper itself

Abstract

Variants of uncertain significance (VUS) are a bottleneck for genetic discovery and complicate clinical decision-making in Alzheimer's disease and related neurological disorders (ADRD). We developed MoVUS: Model for Variants of Unknown Significance, a random-forest approach that integrates functional predictors to classify missense VUS. MoVUS leverages a balanced random forest model trained on dbNSFP v5.1a with high-confidence ClinVar and HGMD labels, using harmonized functional prediction rankscores. MoVUS produced confident, explainable calls, with ~98% accuracy (AUC ~0.998), prioritizing potentially pathogenic candidates and down-ranked likely benign variants on independent validation sets of ClinVar-only and HGMD-only variants. In our discovery analyses on ADRD-implicated variants in dbNSFP and from independent collaborator cohorts, we achieved high-confidence classifications on a majority of the unknown variants (average of 55% of discovery variants). We also had access to medical records and family trees for some variants, further validating our findings. Across held-out and external datasets, MoVUS reports high accuracy alongside confidence scores and helps prioritize actionable candidates, and reduces bias by considering multiple scores for each variant. To facilitate use, we developed a web app for users to browse across 100+ ADRD genes. MoVUS provides transparent, reproducible triage for research follow-up by pairing consensus predictors with SHAP-based visualizations and explanations.

Identifiers

PMID41256702
PMCPMC12622068

What OpenQuestion holds

Textmetadata
LicenceCC0
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.